C
hronic respiratory diseases are set to become the third leading cause of death in the world. 1 In patients with end-stage respiratory disease receiving long-term oxygen therapy (LTOT) and/or home mechanical ventilation (HMV), the median survival is approximately 3 years. 2 In face of this growing public health problem, it is of primary importance to identify the determinants of survival. 2, 3 Chronic respiratory failure due to COPD is more and more regarded as a wasting disease. [3] [4] [5] [6] In patients with COPD, whatever the stage and the type of recruitment, the impact of malnutrition on survival is established. 4, [7] [8] [9] In patients receiving LTOT and/or HMV, regardless of the underlying disease, a French cooperative study 2 showed that body mass index (BMI) predicted survival. We previously reported the high prevalence of malnutrition in neuromuscular and nonneuromuscular outpatients receiving LTOT and/or HMV. 10 The present study focuses on the nonneuromuscular patients and aims to determine the predictive factors of the outcome by the longitudinal follow-up of a 446-patient cohort.
Materials and Methods

Participants
Thirteen outpatient clinics within the Association Nationale de Traitement à Domicile de l'Insuffisance Respiratoire network participated in a prospective survey of hospitalization and death risks in patients receiving home LTOT and/or HMV. Recruitment was performed during the yearly examination as required for reimbursement of home treatment fees. Thus, 446 patients (182 women and 264 men; mean age, 68.5 Ϯ 12.1 years [Ϯ SD]) were included in a cohort study. The minimum planned follow-up was 1 year. Inclusion criteria were age Ͼ 18 years, LTOT and/or HMV for Ͼ 3 months, Pao 2 on room air Յ 8 kPa at initiation of home treatment, and informed consent to examination of nutritional status. Exclusion criteria were neuromuscular diseases, sleep apnea syndrome treated with continuous positive airway pressure, history of exacerbation during the last 3 months, and any condition likely to affect the prognosis within 6 months. Patients with neuromuscular disease (n ϭ 96) were excluded since they present with an intrinsic skeletal muscle disease. Recent exacerbation, Ͻ 3 months, was an exclusion criterion because stable condition was needed to study the potential role of systemic and chronic inflammation. Four respiratory disease groups were considered: COPD corresponding to patients with non-fully reversible bronchial obstruction, bronchiectasis defined on chest CT pattern, restrictive disorders including pulmonary fibrosis and chest wall diseases, and mixed respiratory failure combining restrictive and obstructive defects. This observational study was approved by the French Commission Nationale Informatique et Liberté , and patients gave their informed consent for their participation.
Methods
Body weight and height were recorded at the time of enrollment. Serum albumin, transthyretin (prealbumin), and C-reactive protein levels were determined using conventional methods. Participating laboratories agreed to a blinded quality control. 11 Malnutrition was defined as BMI Յ 20, or serum albumin Ͻ 35 g/L, or serum transthyretin Ͻ 200 mg/L. 6 Blood gases were measured on room air, except in 10 of 191 patients with COPD, 4 of 33 patients with bronchiectasis, 10 of 162 patients with restrictive disorders, and 4 of 60 patients with mixed respiratory failures due to the patient's dependence on LTOT and/or mechanical ventilation. Blood gases were also measured with LTOT and/or HMV. Respiratory function was assessed by FEV 1 , FVC, and 6-min walking distance test on room air. 12, 13 Smoking habits were classified into three categories: nonsmokers, active smokers, and ex-smokers (withdrawal from tobacco Ͼ 3 months). Corticosteroid users were defined as patients who received oral corticosteroids for Ͼ 3 months during the previous year. The number of antibiotic treatment courses was recorded over the same period.
Mean follow-up was 429 Ϯ 169 days, and maximum follow-up was 1,144 days. Two outcome parameters were prospectively recorded: mortality and the number of days of hospitalization. BMI, serum albumin, and transthyretin levels were considered for their predictive value of outcome, together with demographic data, underlying respiratory disease, respiratory function, hemoglobin, C-reactive protein, smoking habits, oral corticosteroid use, and antibiotic treatment courses.
Statistical Analysis
Data distribution of continuous variables was tested using skewness and kurtosis tests. 14 Normally distributed data are reported as mean Ϯ SD and nonnormally distributed as median. Analysis of variance was used to compare normally distributed variables between the respiratory disease groups, with post hoc analysis using Fisher predicted least significant difference test when allowed. When data were not normally distributed, the Kruskal-Wallis test was used with post hoc analysis using Mann and Whitney test with Bonferroni correction. Contingency tables were used for categorical variables. Univariate and multivariate regression analyses were used to study the determinants of hospitalization duration. For survival analysis, parameters having a significant impact on survival after univariate Cox model analysis were tested in a multivariate Cox proportional model analysis. Kaplan-Meier graphs and log-rank tests were performed in order to study the influence of potential predictors on survival. Statview 5 software (SAS Institute; Cary, NC) was used for statistical analysis.
Results
Demographic data, causes of respiratory failure, blood gases, and lung function test results are given in Tables 1, 2 . COPD represented 42.8% of patients, restrictive disorders represented 36.3%, mixed respiratory failure represented 13.5%, and bronchiectasis represented 7.4%. COPD was the most common respiratory disease in male patients (58.4%), and restrictive disorders were the most common respiratory disease in female patients (54.4%). The median Pao 2 in room air of 57 mm Hg shows the severity of One-year and 2-year cumulative survivals were 93% and 69%, respectively. Determinants of survival according to Cox univariate and multivariate model analysis are given in Table 3 . Survival was not influenced by age, sex, etiologies of respiratory failure, Pao 2 with LTOT and/or HMV, and the type of home respiratory assistance. Four parameters were independently associated with survival in the multivariate analysis: C-reactive protein, BMI, Pao 2 on room air, and oral corticosteroids ( Table 3 ). The *Corticosteroid users were defined as patients receiving oral corticosteroids for Ͼ 3 months during the previous year. influence of each of these predictors of survival is depicted in Figure 2 , showing Kaplan-Meier graphs and log-rank tests.
Discussion
Chronic respiratory failure remains of poor prognosis in spite of LTOT and HMV. 2, 9 The aim of this work was to prospectively determine factors of hospitalization rates and survival in patients with hometreated respiratory failure. Outpatients included in this cohort study were characterized by severe and stable respiratory failure secondary to various etiologies. The main result was that survival was independently correlated with systemic inflammation, malnutrition, hypoxemia, and oral corticosteroid use. It is noticeable that, in these patients with end-stage respiratory diseases, the cause of respiratory failure did not influence the outcome.
One limitation of this study could be the heterogeneity of the underlying respiratory diseases. However, in the present series, patients with COPD, restrictive diseases, mixed respiratory failure, and bronchiectasis were not different according to Paco 2 , 6-min walking test, exposure to oral corticosteroid, BMI, and serum albumin levels. Despite differences according to age, gender, pulmonary function test results, need for mechanical ventilation, smoking habits, number of antibiotic courses, and inflammation, a similar outcome was observed whatever the underlying respiratory disease, suggesting a final common pathway at this stage of severe respiratory insufficiency.
One of the main concerns in chronic respiratory failure patients is to identify determinants of hospitalization. As a matter of fact, hospitalization is associated with a high mortality rate during the following year, 15 and is responsible for the main source of costs in patients with COPD. 16 Hospitalizations were found to be independently determined by oral corticosteroid use, low FEV 1 , and elevated C-reactive protein. The role of systemic corticosteroid use in peripheral muscle weakness, a recognized factor of health-care utilization, already established in COPD, 17 was extended to other end-stage respiratory disease in the present study. The impact of low FEV 1 on the occurrence of exacerbations is admitted in the setting of COPD. 18 Data from the present series demonstrate the predictive value of low FEV 1 on the hospitalization risk whatever the cause of chronic respiratory failure.
The influence of hypoxemia on survival and the interest of oxygen therapy have clearly been demonstrated during COPD in the early 1980s in randomized controlled studies, 19, 20 and more recently as a risk factor for hospitalization for acute exacerbation during COPD. 18 Similarly, the prognostic effect of low BMI has already been documented in patients with homeassisted respiratory failure and particularly during COPD. 2,7-9 A major potentially modifiable risk is the use of prolonged oral corticosteroids. In a retrospective study, 21 oral corticosteroid therapy has been shown to be responsible for a dose-related increase in mortality risk in ambulatory patients with COPD admitted to a rehabilitation center. Similar adverse effects of oral corticosteroids have been observed in prospective studies, in women with COPD receiving LTOT, 22 and after hospitalization for acute exacerbation of COPD. 23, 24 Our data showed that the pejorative effect of systemic corticosteroids also concerns home-treated end-stage respiratory diseases. This observation is important to consider since positive effects of prolonged oral corticosteroids are not established in COPD, bronchiectasis, chest wall disease, advanced diffuse infiltrative diseases, or mixed respiratory failure. Myopathy is one of the most severe complications of prolonged treatment with oral corticosteroids. 25 In patients with COPD, corticosteroids adversely affect both respiratory and peripheral muscle function. 26 -29 As the decrease in the muscle amino acid reservoir is associated with alterations of several key physiologic functions such as tissue regeneration and immune defense, muscle wasting due to oral corticosteroids may explain their detrimental consequences on patient outcome. 30 The main finding of this study was that systemic inflammation, as evaluated by serum C-reactive protein, was related to the risk of hospitalization and appeared to be the best prognostic indicator of survival. Although the relationship between C-reactive protein and survival is well recognized in cardiovascular diseases, [31] [32] [33] it had not been previously demonstrated in chronic respiratory failure. These data support the concept that a subgroup of patients with chronic respiratory failure suffers from a systemic inflammation, which in turn may account for an increased morbidity and mortality.
Routine monitoring and management of patients with chronic respiratory failure rely mostly on Pao 2 in room air and FEV 1 . C-reactive protein and BMI now appear of clinical relevance to assess the risk of hospitalization and death and should be included in the follow-up of patients receiving LTOT or HMV. This work stresses that, in patients with end-stage respiratory disease, maintenance treatment with oral corticosteroids is an independent risk factor of death and should be avoided in most cases.
